Gradual allograft rejection after initial good engraftment may occur with simultaneous autologous reconstitution particularly in patients receiving nonmyeloablative conditioning. Careful post-transplant follow-up of the chimerism status can reveal these cases early on, when the immunological balance may still be shifted to the donor cells. We describe two children with nonmalignant diseases, in whom imminent rejection of their sibling allografts was prevented with donor lymphocyte transfusions (DLT). DLT dosing and timing need to be individually guided by monitoring of the chimerism status.
sions; chimerism in bone marrow; monitoring of bone marrow chimerism Allograft rejection is not usually a problem in children with malignant diseases who receive full myeloablative conditioning often including total body irradiation. The type of donor has some influence on rejection risk; grafts from both matched siblings and unrelated donors engraft well, while by using cord blood grafts, nonengraftment occurs with an incidence of 10-20%.
1,2 Also T-cell depletion increases the risk of nonengraftment.
By using traditional donors, nonengraftment has primarily been observed in patients with nonmalignant diseases not requiring conditioning as strong as, for example, those with leukemia. A good example is aplastic anemia, 3 but today patients with many other nonmalignant diseases are also transplanted including those with a variety of benign blood diseases, immunodeficiencies, and metabolic diseases. Nonengraftment figures may be close to 30% in these patients. 4, 5 In our experience, gradual graft rejection after initial good engraftment is also fairly common. While autologous reconstitution takes place simultaneously and gradually replaces the graft, this condition may initially be overlooked unless followed up carefully.
In cases of allograft rejection or nonengraftment, repeated stem cell infusions with more or less preparative treatment have mostly been used to date. 6 More recently, donor lymphocyte transfusions (DLTs) have also been used, either prophylactically in cases at increased risk of nonengraftment, as with haploidentical or unrelated donor grafts and/or with T-cell-depleted grafts, 7, 8 or in patients with a failing graft as indicated by decreasing donor chimerism, with a few successful cases reported. 3, [9] [10] [11] Today, modern techniques allow post-transplant followup of minimal residual disease status as well as chimerism status, and, consequently, imminent rejections may be caught early. We describe two children transplanted for benign hematological diseases in whom their sibling allografts were saved by using a series of DLT.
Patients

Case 1
This boy had Diamond-Blackfan anemia (DBA), a congenital pure red cell aplasia which proved to be resistant to corticosteroid therapy. At 1 year and 4 months of age, allogeneic BMT was performed from his HLA-identical, 4-year-old sister. He was conditioned with cyclophosphamide at 50 mg/kg/day Â 4 days, plus antilymphocyte globulin of 30 mg/kg/day Â 5 days. The nucleated cell dose given was 4.8 Â 10 8 /kg, and routine GVHD-prophylaxis with cyclosporine and short methotrexate was used. He engrafted promptly and well (ANC4500 Â 10 6 /l on day +11), and also demonstrated a reticulocytosis of 5% 3 weeks post-transplant.
Chimerism studies were performed serially based on the XX/XY constellation. Donor chimerism of 28, 13 and 5% was demonstrated at 5, 7 and 10 weeks post transplant, respectively. At 5 weeks, cyclosporine was discontinued. During the same time, peripheral blood reticulocytes decreased from 5 to 0.5%, and no more erythroid precursors were seen in the marrow from week 7 on. The patient was otherwise well, and no GVHD developed. The sister's allograft had been rejected within 3 months post transplant, and autologous reconstitution had taken place.
After 1 year, at 2 years and 3 months of age, allogeneic BMT from the same donor was reattempted. This time the preparative regimen consisted of cyclophosphamide at 50 mg/kg/day Â 4 days, a prolonged course of antilymphocyte globulin of 30 mg/kg/day Â 10 days, plus nodal irradiation of 6 Gy. The nucleated cell dose was 7.9 Â 10 8 /kg, again given unmanipulated and fresh to the patient. Routine GVHD prophylaxis with cyclosporine and methotrexate was initiated.
The patient again engrafted promptly and well (ANC of 500 Â 10 6 /l on day +10), as was also indicated by a reticulocytosis of 5.9% 3 weeks post-transplant. The first chimerism analysis at 4 weeks post-transplant revealed 65% donor cells and 35% recipient cells in the bone marrow. In view of the previous graft having gradually failed, this was interpreted as imminent graft rejection. At that point GVHD prophylaxis was discontinued and DLTs were initiated.
Donor leukocytes were obtained, with informed consent from the parents and with official consent from the State Medical Board (as is customary regarding minors in Finland), by a single apheresis procedure from the sister, and frozen in multiple aliquots of a known concentration of CD3-positive cells, in liquid nitrogen. A total of 11 DLTs were administered, initially at 2 and later up to 6-week intervals during the following year, in amounts increasing from 2 Â 10 5 to 1.1 Â 10 7 of donor CD3-positive T-cells per kg of recipient weight. The chimerism status of the bone marrow immediately improved, reaching a donor/recipient status of 99/1% by 4 months post transplant (Figure 1 ). Bone marrow erythropoiesis markedly improved after two DLTs. The patient has been in excellent health during follow-up, with no symptoms or signs of GVHD, and on no BMT-related medications. He is currently very well, running a hemoglobin concentration of about 120 g/l and a reticulocyte count of 1-1.5%.
Case 2
This boy had dyserythropoietic anemia of undefined type and a somewhat fluctuating course. After 6 years of age he remained red cell transfusion-dependent. At 8 years and 10 months of age he underwent allogeneic BMT from his HLA-identical 6-year-old sister. He was conditioned with cyclophosphamide at 50 mg/kg/day Â 4 days, antilymphocyte globulin of 30 mg/kg/d Â 7 days, and total nodal irradiation of 6 Gy. The nucleated cell dose given was 2.8 Â 10 8 /kg. Routine GVHD prophylaxis with cyclosporine and short methotrexate was given. He initially engrafted promptly and well (ANC 4500 Â 10 6 /l on day +16). Routine chimerism follow-up 4 weeks post transplant, based on the XX/XY constellation, revealed donor chimerism of 80% in the bone marrow, and 72% 1 week later. This was interpreted as imminent graft rejection. GVHD prophylaxis was discontinued at 4 weeks, and DLTs were initiated 5 weeks post transplant.
Donor lymphocytes were obtained, as in case 1, by a single apheresis procedure from the donor sister. The DLTs were initiated at a dose of 3 Â 10 5 of CD3-positive cells per kilogram recipient weight. However, the donor chimerism decreased from 72% at 5 weeks to 68% at 7 weeks, and further to 47% at 9 weeks post transplant, so T-cell doses were consequently increased to 2 Â 10 7 /kg and further to 1 Â 10 8 /kg (Figure 2) . Improvement in the chimerism status followed subsequently and 4 weeks after the fourth DLT, a full 100% donor chimerism was achieved. However, at 13 weeks post transplant a Coombs test (direct antiglobulin test) positive immune pancytopenia developed with precipitous anemia and decreasing platelet and absolute neutrophil counts, while marrow production of all three cell lines was good. This was interpreted as an AIHA/Evan's syndrome. Also acute GVHD grade I of the skin, gut and liver developed. No further DLTs were administered, and the 100% donor chimerism remained stable unmaintained. The patient was started on prednisone at 2 mg/kg/day, with resolution of the skin and gut GVHD but little effect upon the AIHA. He then was given 3 weekly doses of Rituximab (Mabthera R ) at 375 mg/ m 2 /dose. The AIHA resolved, the direct Coombs test turned negative, and the peripheral blood B-lymphocytes, measured as CD19-and CD20-positive cells, decreased from 39% to zero. The prednisone was tapered off, and monthly intravenous immunoglobulin prophylaxis was instituted.
The AIHA/Evan's syndrome did not totally resolve away, since after 3 months the patient again turned Coombs-test-positive with an increasing tendency to anemia. One more infusion of Rituximab was given, successfully. After 2 months, a further Coombs-testpositive anemia occurred, and since no CD19 and CD20 positive cells were detected in the peripheral blood, instead of Rituximab, intravenous immunoglobulin was administered at 1 g/kg/day as a 5-day course, with success. After a post-transplant follow-up of 1 year, some limited and mild cutaneous chronic GVHD is present. There was also an episode of CMV-enteritis. The patient has remained at about 100% of donor chimerism, and is currently doing well on no medications other than the monthly IVG prophylaxis.
Discussion
Our two cases demonstrate imminent allograft rejection. Case 1 had a history of previous graft rejection from the same donor 1 year earlier, and had not received total body irradiation this time either. The donor chimerism of only 65% at 4 weeks post transplant made us fear that graft rejection was again going to take place. In case 2, rejection was clearly imminent, with a steep downward course to 47% donor chimerism (Figure 2) . Series of DLTs were administered to both of these children; case 1 received lower doses during a prolonged course, while case 2 received abruptly increasing doses in order to rescue the graft, with the DLTs being discontinued after four doses. Both attempts were successful in terms of preventing allograft rejection and achieving close to 100% donor chimerism. While case 1 seemingly had an optimal course without any GVHD, case 2, as concluded retrospectively, probably received T-cell doses somewhat too high and ended up with GVHD including the AIHA/Evan's syndrome as a manifestation.
A certain number of additional donor T-cells, ranging from 2.5 Â 10 /kg 3, 7 have in general been utilized, as compared to doses required for minimal residual disease eradication or post-transplant relapses in patients with leukemia, for whom doses in the order of 10 7 -10 8 /kg have been used. In patients with imminent graft rejection dosing is difficult because it has to be individually tailored. Even though DLT dosing is guided by follow-up of chimerism status, the effect will take some 2-3 weeks, leading to the potential risk of overdosing.
The clear adverse effect of individual DLT overdosing is the development of GVHD, the risks depending on such issues as type of donor (matched sibling vs URD vs haploidentical donor). Both of our cases had HLAidentical sibling donors, explaining why they tolerated the T-cell doses given. The risk of GVHD also depends on DLT timing, GVHD risk being higher during the first 2 months post-transplant, and reduced after day 100. 7 GVHD prophylaxis also plays a role. In our experience and that of others, 9 discontinuation of cyclosporine may sometimes be sufficient to shift the balance in favor of the donor cells. If DLTs result in GVHD, the treatment of GVHD may also be tricky, in the worst case destroying the benefits for donor chimerism already achieved. We therefore preferred Rituximab for our patient (case 2) in treating the AIHA/Evan's syndrome 12 so that the prednisolone, acutely initiated, could be tapered off.
We used DLTs in a series administered first at a 2-week interval and later at 4-6 week intervals, according to the earlier experience of others. Our patients have been followed up for 1 year after transplantation, remaining with stable donor chimerism close to 100%. We do not know, however, for how long this situation will continue unmaintained, and thus close follow-up is still needed. As far as maintenance DLT goes, this may also become a matter of availability, particularly regarding cord blood or URD grafts. Even with sibling donors, it may not be ethical for minors to undergo repeat apheresis procedures. Furthermore, eradication of all host cells might even not be necessary to achieve a stable mixed chimerism.
Quantitative follow-up of chimerism status based on the XX/XY constellation, as in our two cases, is only possible in a proportion of donor-recipient pairs. However, modern techniques allow post-transplant engraftment monitoring by quantitative PCR based amplification of short tandem repeat markers and this technique is suitable for a sequential analysis of chimerism from peripheral blood mononuclear cells, and can cover virtually all transplant patients if so desired. Systematic follow-up enables us to take therapeutic measures before the window of opportunity has been passed.
We conclude that the monitoring of post-transplant chimerism status is important, not only in the follow-up of patients with leukemia, but also in patients at risk of graft rejection and autologous reconstitution due to type of the graft and/or nonmyeloablative preparative regimens. The use of DLTs seems encouraging in preventing imminent graft rejection, the effects and adverse effects being doseand timing-related. We need to gain more experience of this new immunotherapeutic modality.
